Sanofi (NASDAQ:SNY) Stake Lifted by HBK Sorce Advisory LLC

HBK Sorce Advisory LLC increased its stake in Sanofi (NASDAQ:SNY) by 10.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,267 shares of the company’s stock after acquiring an additional 391 shares during the period. HBK Sorce Advisory LLC’s holdings in Sanofi were worth $206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC bought a new stake in Sanofi during the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares in the last quarter. Sierra Ocean LLC bought a new stake in Sanofi during the fourth quarter worth approximately $44,000. Finally, Versant Capital Management Inc bought a new stake in Sanofi during the fourth quarter worth approximately $54,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $57.75 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $146.56 billion, a PE ratio of 23.19, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm has a 50 day simple moving average of $53.65 and a 200 day simple moving average of $52.83.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.